Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Down 33.4% in July

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the recipient of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 8,407 shares, a decrease of 33.4% from the June 30th total of 12,617 shares. Based on an average trading volume of 2,362 shares, the short-interest ratio is presently 3.6 days. Approximately 4.2% of the shares of the company are short sold.

Institutional Trading of Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently bought a new position in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC bought a new stake in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF at the end of the most recent reporting period.

Amplify Weight Loss Drug & Treatment ETF Stock Down 1.8%

Shares of THNR stock opened at $25.40 on Friday. The firm has a market cap of $5.08 million, a P/E ratio of 24.31 and a beta of 0.37. The company has a 50 day moving average of $25.17 and a 200-day moving average of $25.16. Amplify Weight Loss Drug & Treatment ETF has a 12-month low of $21.70 and a 12-month high of $27.28.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.